Julian Lord

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Ilypsa, Inc. operates a biopharmaceutical firm. It develops renal care pharmaceutical products. The company was founded on March 6, 2003 and is headquartered in Thousand Oaks, CA.

Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA.

Part of JWGenesis Financial, Inc., Genesis Merchant Group Securities LLC provides security brokerage and dealer services. The company is based in Miami, FL. The company was founded by Barry S. Rosenstein. Genesis Merchant Group Securities was acquired by JWGenesis Financial, Inc. on June 12, 1998 for $15.95 million.

Delphi Ventures Inc (Delphi Ventures) is a venture capital firm founded in 1988 by James Bochnowski. The firm is headquartered in San Mateo, California.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.

Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019.

Macrotarg Ltd. is a biotechnology research and British experimental development company founded in 2007. The private company is based in Winnersh, UK.

Part of Neurocrine Biosciences, Inc., Diurnal Ltd. is a European, British UK-headquartered specialty pharmaceutical company founded in 2004. The company is based in Cardiff, UK. The company is dedicated to developing lifelong treatments for rare and chronic endocrine conditions.

Nasdaq Corporate Solutions International Ltd. develops and manages software for corporate communications and reputation management solutions. The company was founded in and is headquartered in London, the United Kingdom.

Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The company is based in London, UK.

Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Medica Reporting Ltd. provides radiology reporting services. It offers clinical services, including an on demand flexible radiology reporting service, seamless integration to in-house systems, emergency reporting services, multiple modalities and sub-specialties, and Web based report delivery to referrers. The company also provides technology offerings, such as DICOM storage solutions, picture archiving and communication systems, radiology information systems, remote reporting systems and tools, Web electronic patient record and results reporting solutions, purchase order and invoice processing systems, and project management and implementation services. Medica Reporting was founded in 2004 and is headquartered in Hastings, the United Kingdom.

Part of Medica Group Plc, JCA Seminars Ltd. is a medical training company based in Hastings, UK. The British company offers worldwide radiology and medical CPD training in various specialist fields such as gynae, breast, cardiac CT, MRI, and paediatrics. The company welcomes sponsors from different backgrounds and specialities such as Phantoms, Ultrasound Equipment, and Recruitment agencies. JCA Seminars emphasizes the importance of bowel cancer screening in detecting bowel cancer at an early stage. The company was founded in 2003 by Jane Elizabeth Chandler, who has been the CEO since then. JCA Seminars was acquired by Medica Group Plc on March 29, 2023 for $1.73 million.

Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The company is based in London, UK.

Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010.